Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) Profit Outlook
We feel now is a pretty good time to analyse Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) business as it appears the company may be on the cusp of a considerable accomplishment. Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. The US$133m market-cap company posted a loss in its most recent financial year of US$27m and a latest trailing-twelve-month loss of US$35m leading to an even wider gap between loss and breakeven. Many investors are wondering about the rate at which Unicycive Therapeutics will turn a profit, with the big question being “when will the company breakeven?” Below we will provide a high-level summary of the industry analysts’ expectations for the company.
Unicycive Therapeutics is bordering on breakeven, according to the 9 American Biotechs analysts. They expect the company to post a final loss in 2026, before turning a profit of US$56m in 2027. Therefore, the company is expected to breakeven just over a year from now. How fast will the company have to grow each year in order to reach the breakeven point by 2027? Working backwards from analyst estimates, it turns out that they expect the company to grow 48% year-on-year, on average, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.
Given this is a high-level overview, we won’t go into details of Unicycive Therapeutics' upcoming projects, however, take into account that typically a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.
View our latest analysis for Unicycive Therapeutics
Before we wrap up, there’s one aspect worth mentioning. Unicycive Therapeutics currently has no debt on its balance sheet, which is rare for a loss-making biotech, which usually has a high level of debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.
Next Steps:
There are too many aspects of Unicycive Therapeutics to cover in one brief article, but the key fundamentals for the company can all be found in one place – Unicycive Therapeutics' company page on Simply Wall St. We've also put together a list of essential factors you should further research:
- Valuation: What is Unicycive Therapeutics worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Unicycive Therapeutics is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Unicycive Therapeutics’s board and the CEO’s background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.